SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.
SeLux Diagnostics has raised $48.0M in total funding. The most recent round was Series D. The last funding was announced in April 2024.
SeLux Diagnostics's investors include RA Capital Management, Sands Capital Ventures, National Institutes of Health, Northpond Ventures, Schooner Capital.
SeLux Diagnostics is headquartered in Charlestown, United States.
SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.
SeLux Diagnostics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SeLux Diagnostics — Funding & Investors." VCBacked, April 1, 2024, https://www.vcbacked.co/company/selux-diagnostics. Accessed July 19, 2026.
VCBacked. (2024). SeLux Diagnostics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/selux-diagnostics
{{cite web |title=SeLux Diagnostics — Funding & Investors |url=https://www.vcbacked.co/company/selux-diagnostics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated